Yahoo Web Search

Search results

    • Small Business - The Brewton Standard | The Brewton Standard

      The Brewton Standard· 1 week ago

      Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor